Hyundai PharmㆍJW ShinyakㆍHanmi PharmㆍSamil PharmㆍHandok Rank Among Top 100 in Q3 Stock Price Gains

[NEWSMP] Korean pharmaceutical and biotech stocks generally struggled to gain momentum in the third quarter. Among the constituents of the pharmaceutical indices on the two markets, four KOSPI-listed stocks and two KOSDAQ-listed stocks ranked among the top 100 in terms of share price gains. (All figures are based on adjusted share prices)

On the KOSPI, only 20 of the 49 constituents of the pharmaceutical index, excluding preferred shares, recorded share price gains during the period, accounting for less than half of the total.

Among them, Hyundai Pharm surged 46.60%, ranking 22nd and becoming the only pharmaceutical index constituent across the two markets to place within the top 50.

Hanmi Pharm followed with a 25.53% gain, ranking 59th, while Samil Pharmaceutical rose 21.67% to rank 77th and Handok gained 19.24% to rank 98th, with all three ranking among the top 100.

Kwangdong Pharmaceutical rose 14.03% to rank 158th, while Ilsung IS gained 13.80% to rank 163rd. As a result, all six stocks that posted double-digit gains ranked within the top 200.

Shinpoong Pharmaceutical gained more than 5% and ranked within the top 300, while the remaining stocks stayed outside the top 300 as their gains were below 5%.

A similar trend was seen in the KOSDAQ pharmaceutical index. Excluding newly listed companies, only 52 of its 129 constituents posted gains, accounting for less than half of the total.

Among them, SCL Science surged 55.95% to rank 62nd, while JW Shinyak jumped 52.22% to rank 70th, putting both stocks among the top 100.

Samik Pharmaceutical followed with a 32.46% gain, ranking 158th, while Genome & Company rose 32.12% to rank 163rd. Both stocks, which gained more than 30%, ranked within the top 200.

Komipharm, Jetema, GC Wellbeing, Polaris AI Pharma, Genolution, Bioneer, Daehwa Pharmaceutical, BNC Korea, Sinil Pharmaceutical and HLB Life Science, all of which posted gains in the 20% range, ranked between 200th and 300th place.

In addition, Seegene, Green Lifescience, Kyungnam Pharm, Sugentech, WooGene B&G, Dongkook Lifescience and Bio-FD&C, all of which posted gains of at least 15%, ranked within the top 400.

RP Bio, Dongkook Pharmaceutical, Vivozon Pharmaceutical, Withus Pharmaceutical, Sama Pharmaceutical, iNtRON Biotechnology and DuChemBio also posted double-digit gains, although they remained outside the top 400.